Global Lipid POCT Market – Industry Trends and Forecast to 2031

Global Lipid POCT Market, By Type (Instruments, Consumables and Kits), Application (Hyperlipidemia, Hypertriglyceridemia, Hyperlipoproteinemia, Familial hypercholesterolemia, Tangier Disease, Others), Mode (Prescription-Based Testing, OTC-Based Testing), Brand (Roche Reflotron, Roche Cobas B 101, Alere Cholestech LDX, Alere Afinion, Samsung Labgeo, PTS Cardiochek, Others), Platform (Lateral Flow Assays (Immunochromatography Tests), Molecular Diagnostics, Immunoassays, Dipsticks, Microfluidics), End User (Hospitals, Professional Diagnostic Centers, Home Care, Research Laboratories, Other End Users), Distribution Channel (Direct Tender, Retail Sales) – Industry Trends and Forecast to 2031.

Lipid POCT Market Analysis and Size

The new biotechnological advancements have been creating immense boosting factors and drive the growth of the lipid POCT market. The high cost of products can hamper the growth of the lipid POCT market. The rising healthcare expenditure is expected to act as an opportunity for the growth of the lipid POCT market. The lack of alignment with test results obtained from laboratories is creating an immense challenge for the lipid POCT market.

Data Bridge Market Research analyzes that the global lipid POCT market which was USD 173.17 million in 2023, is likely to reach USD 258.20 million by 2031, and is expected to undergo a CAGR of 5.1% during the forecast period. “Instruments” dominates the type segment of the market owing to the growing demand for better methods for treatment in patients. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Lipid POCT Market Scope and Segmentation

Market Definition

POCT is characterized as testing which can be done close to the patient where a medical decision can be made immediately including the results and monitoring. Lipid POCT is also called with-patient testing of lipid and allows physicians to accurately measure real-time, lab-quality diagnostic results within less than minutes as compared to hours.

Global Lipid POCT Market Dynamics

Drivers

• Increasing prevalence of cardiovascular diseases

The rising incidence of cardiovascular diseases, such as heart disease and stroke, is driving the demand for lipid testing. Lipid POCT allows for quick and convenient testing of lipid profiles, enabling early detection and management of these condition.

• Technological advancements

Advancements in technology have led to the development of more accurate and reliable lipid POCT devices. These devices provide rapid results with high precision, allowing for immediate diagnosis and treatment decisions.

Opportunities

• Expansion in home healthcare

With the increasing trend of home healthcare, there is an opportunity for Lipid POCT devices to be used by individuals in the comfort of their own homes. Home-based lipid testing can provide convenience and regular monitoring for patients with cardiovascular risk factors or those on lipid-lowering medications. This opportunity allows for better patient engagement and self-management of lipid levels.

• Integration with digital health platforms

The integration of Lipid POCT devices with digital health platforms presents an opportunity for improved data management and patient care. By connecting lipid testing devices to electronic health records or mobile applications, healthcare providers can access real-time data, track trends, and provide personalized interventions. This integration also facilitates remote monitoring and telemedicine, enabling healthcare professionals to remotely monitor lipid levels and provide timely guidance to patients.

Restraints/Challenges

• Regulatory challenges

The regulatory landscape for point-of-care testing can be complex and varies across different regions. Obtaining regulatory approvals and ensuring compliance with quality standards can be time-consuming and costly for manufacturers of lipid POCT devices. These regulatory challenges can hinder the entry of new players into the market and slow down the overall growth of the Lipid POCT market.

• Accuracy and standardization

Ensuring the accuracy and standardization of lipid testing results across different Lipid POCT devices can be challenging. Variations in testing methodologies, reagents, and calibration methods can lead to inconsistent results. Standardization efforts are required to establish uniform lipid testing protocols and ensure the reliability and comparability of lipid test results obtained from different devices. Addressing this challenge is crucial to build trust and confidence in lipid POCT among healthcare professionals and patients.

This lipid POCT market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the lipid POCT market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.

Recent Development

• In November 2020, SD Biosensor, INC. announced its partnership with DKSH Korea to develop pharmacy blood sugar business. This will help the company to diversify its market in coming years

Global Lipid POCT Market Scope

The lipid POCT market is segmented on the basis of type, application, mode, brand, platform, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Instruments
• Consumables and Kits

Application

• Hyperlipidemia
• Hypertriglyceridemia
• Hyperlipoproteinemia
• Familial hypercholesterolemia
• Tangier Disease
• Others

Mode

• Prescription-Based Testing
• OTC-Based Testing

Brand

• Roche Reflotron
• Roche Cobas B 101
• Alere Cholestech LDX
• Alere Afinion
• Samsung Labgeo
• PTS Cardiochek
• Others

Platform

• Lateral Flow Assays (Immunochromatography Tests
• Molecular Diagnostics
• Immunoassays
• Dipsticks
• Microfluidics

End User

• Hospitals
• Professional Diagnostic Centers
• Home Care
• Research Laboratories
• Other End Users

Distribution Channel

• Direct Tenders
• Retail Sales

Global Lipid POCT Market Regional Analysis/Insights

The lipid POCT market is analyzed and market size insights and trends are provided by country, type, application, mode, brand, platform, end user and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Russia, Poland, Switzerland, Netherlands, Hungary, Austria, Norway, Ireland, Turkey, Lithuania, rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Egypt, and rest of Middle East & Africa.

North America is expected to dominate the market due to the increasing prevalence of chronic diseases and rising technological advancements and increasing diagnosis rate and awareness about the cardiovascular disease.

Asia-Pacific is expected to witness significant growth during the forecast period of 2024 to 2031 due to the increasing diagnosis rate and awareness about the cardiovascular disease.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The lipid POCT market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the lipid POCT market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the lipid POCT market.

Competitive Landscape and Lipid POCT Market Share Analysis

The lipid POCT market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the lipid POCT market.

Some of the major players operating in the lipid POCT market are:

• SD Biosensor,INC. (South Korea)
• Abbott (U.S.)
• PTS Diagnostics (U.S.)
• Trinity Biotech (Ireland)
• F.Hoffmann-La Roche Ltd. (Switzerland)
• Nova Biomedical (U.S.)
• Calligari Srl (Italy)
• AMD SOLUTIONS (Argentina)
• EuroMedix (Netherlands)
• Siemens Healthcare GmbH (A Subsidiary of Siemens) (Germany)
• TASCOM (Japan)
• General Life Biotechnology Co., Ltd. (Taiwan)
• MICO BIOMED (South Korea)
• Jant Pharmacal Corporation (U.S.)
• Samsung Medison Co., Ltd. (South Korea)
• A. Menarini Diagnostics s.r.l (Italy)
• ACON Laboratories, Inc. (U.S.)
• PRIMA Lab SA (Poland)
• Quest Diagnostics Incorporated (U.S.)
• SKYLA CORPORATION (Japan)